The activities of 17 new rhodium drug complexes were determined against Leishmania donovani promastigotes. The five most active salts were selected: [RhIII(2-amino-6-ethoxybenzothiazole)4Br2]+Br–; [RhIII(2-bromothiazole)4(Br)2]+Br–; [RhIII(mefloquine)4(Cl)2]+Cl–; [RhIII(2-mepacrine)4(Cl)2]+Cl–, and [RhIII(oxamniquine)4(Cl)2]+Cl–, which induced growth-inhibition rates of more than 50% at 24 h of treatment and at the maximum dosage tested. The cytotoxicity assays on the macrophage cell line J-774 showed high cytotoxicity for the salts [RhIII (mefloquine)4(Cl)2]+Cl–, [RhIII(2-mepacrine)4(Cl)2]+Cl– and [RhIII(oxaminquine)4(Cl)2]+Cl– with a percentage of specific 15Cr release of 49.3, 64.8 and 53.2% at 24 h of incubation and 100 µg/ml. Meanwhile, assays of the other compounds showed practically no cytotoxicity. The ultrastructural studies in the flagellates treated with the salt [RhIII(2-amino-6-ethoxybenzothiazole)4Br2]+Br– showed some alterations in the nucleus of the parasites with a very condensed chromatin and an electrodense endosome. This compound showed a high in vivo activity in parasitized Wistar rats.